Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis

British Journal of Dermatology

Volumn 159, Issue 5, 2008, Pages 1116-1123

  Gerdes, S ^a   Zahl, V A ^a   Knopf, H ^b   Weichenthal, M ^a   Mrowietz, U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Comedication; Comorbidities; Psoriasis

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIGOUT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUMARIC ACID DERIVATIVE; HORMONE; METHOTREXATE; MINERAL; MORPHINE; NITRATE; PSYCHOTROPIC AGENT; RETINOID DERIVATIVE; THYROID HORMONE; VITAMIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; EPILEPSY; GERMANY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRIORITY JOURNAL; PSORIASIS;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; COMORBIDITY; DRUG INTERACTIONS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYPHARMACY; PSORIASIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 54249136408     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08786.x     Document Type: Article

References (26)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007 370 : 263 71.
2. Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol 2006 126 : 1205 6.
3. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006 298 : 309 19.
4. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003 4 : 441 7.
5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 6.
6. Pearce DJ, Morrison AE, Higgins KB et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005 16 : 319 23.
7. Cohen AD, Bonneh DY, Reuveni H et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol (Stockh) 2005 85 : 299 303.
8. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000 1 : 159 65.
9. Bellach BM, Knopf H, Thefeld W. [The German Health Survey. 1997/98]. Gesundheitswesen 1998 60 (Suppl. 2 S59 68.
10. Robert Koch-Institut. Public Use File BGS98, Bundes-Gesundheitssurvey 1998. Berlin : Robert Koch-Institut, 2000.
11. Knopf H, Melchert HU. Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Konsumverhalten in Deutschland. Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin : Robert Koch-Institut, 2003 1 132.
12. Gilleaudeau P, Vallat VP, Carter DM et al. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993 28 : 490 2.
13. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 298 : 321 8.
14. Akay A, Pekcanlar A, Bozdag KE et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002 16 : 347 52.
15. Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression. Dermatology 2006 212 : 123 7.
16. Yang Y, Koh D, Khoo L et al. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. Int J Dermatol 2005 44 : 925 9.
17. O'Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol 2006 5 : 426 32.
18. Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986 172 : 298 304.
19. Kwan SY, Lin JH, Su MS. Coexistence of epilepsy, myasthenia gravis and psoriasis vulgaris. Zhonghua Yi Xue Za Zhi (Taipei) 2000 63 : 153 7.
20. Abel EA, DiCicco LM, Orenberg EK et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986 15 : 1007 22.
21. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007 143 : 1559 65.
22. van de Kerkhof PC, Kragballe K, Austad J et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006 16 : 167 71.
23. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004 19 : 225 30.
24. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
25. Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 156 : 271 6.
26. Wakkee M, Thio HB, Prens EP et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007 190 : 1 9.